Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT: NCT04905693 · ENROLLING_BY_INVITATION

NCT IDNCT04905693
StatusENROLLING_BY_INVITATION
Start Date2022-09-06
Completion2026-06

Brief Summary

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

Frequently Asked Questions

What is Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease?

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease is a clinical trial registered under NCT04905693. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT04905693?

The current status of NCT04905693 (Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease) is: ENROLLING_BY_INVITATION.

When did Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease start?

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease started on 2022-09-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑